NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Tvardi Therapeutics, Inc. (TVRD) Stock Analysis

Tvardi Therapeutics, Inc. (TVRD) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

TVRD

$1.02

+$0.03 (+2.82%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TVRD with… →

TVRD Key Statistics

As of Oct 21, 2026
Trading
Open
$1.02
Previous Close
$0.99
Day's Range
1.02–1.09
52-Week Range
0.93–5.90
Volume
136.70K
Valuation
Market Cap
$13.61M
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−2.84
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$18.21M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
13.34M
1-Year Return
−82.14%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
243.89K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, TVRD closed at $1.02, −82.14% over 1 year.

Tvardi Therapeutics, Inc. (TVRD) has a market capitalization of $13.61M.

In fiscal 2025, TVRD reported revenue of $0.00.

TVRD Stock Return by Calendar Year

Tvardi Therapeutics, Inc. (TVRD) 10-year return: what $10,000 became

1 year
$10,000 $1,786
−82.14%
5 years
$10,000 $22
−99.78%
10 years
$10,000 $36
−99.64%

If you had invested $10,000 in Tvardi Therapeutics, Inc. (TVRD) 10 years ago, at the close on October 21, 2016, it would have been worth $36 at the close on October 21, 2026: −99.64% in total, −43.06% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−76.28%
2025−76.58%
2024−31.36%
2023−93.08%
2022−11.82%
2021−19.50%
2020−6.08%
2019+23.92%
2018+6.21%
2017+31.75%
2016 (partial year)+58.26%

As of October 21, 2026.

TVRD Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$18.21M—
2024$0.00−$29.40M—
2023$0.00−$17.35M—
2022$0.00−$20.54M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$26.75M−$18.21M—
2024$0.00—−$28.11M−$29.40M—
2023$0.00—−$18.67M−$17.35M—
2022$0.00—−$21.19M−$20.54M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 11 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Tvardi Therapeutics, Inc. (TVRD) carries a market capitalisation of $13.61M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 12.

The 52-week range on file runs from $0.93 to $5.90. The most recent close on file for TVRD is $1.02, dated October 21, 2026. That is +$0.03 (+2.82%) against the previous close. The latest close sits 9.68% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $18.21M. Trailing earnings per share are −2.84.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Over the trailing twelve months the total return is −82.14%. Measured over 10 years, that is −43.06% a year compounded. Daily returns over the trailing 10 years annualize to a volatility of 91.08%.

Growth & Income

No dividend is on file for TVRD.

So far in 2026 the total return is −76.28%. The strongest complete calendar year on file is 2017 at +31.75%; the weakest is 2023 at −93.08%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Tvardi Therapeutics, Inc. (TVRD) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Tvardi Therapeutics, Inc. TVRD $13.61M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Tvardi Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Tvardi Therapeutics, Inc.

Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.

Visit website →